EPO & GSK3beta
In 2016, a study I co-authored was ranked amongst the most cited papers in Biological Psychiatry showing that cognitive improvements in EPO-treated patients with mood disorders involves increased hippocampal volume. We have now written a Review paper about EPO, cognition, depression and its underlying molecular mechanisms centred around GSK3beta. The manuscript has just been accepted into Translational Psychiatry…
GSK3β: a plausible mechanism of cognitive and hippocampal changes induced by erythropoietin treatment in mood disorders?
Abstract: Mood disorders are associated with significant psychosocial and occupational disability. It is estimated that major depressive disorder (MDD) will become the second leading cause of disability worldwide by 2020. Existing pharmacological and psychological treatments are limited for targeting cognitive dysfunctions in mood disorders. However, growing evidence from human and animal studies has shown that treatment with erythropoietin (EPO) can improve cognitive function. A recent study involving EPO-treated patients with mood disorders showed that the neural basis for their cognitive improvements appeared to involve an increase in hippocampal volume. Molecular mechanisms underlying hippocampal changes have been proposed, including the activation of anti-apoptotic, antioxidant, pro-survival and anti-inflammatory signalling pathways. The aim of this review is to describe the potential importance of glycogen synthase kinase 3-beta (GSK3β) as a multi-potent molecular mechanism of EPO-induced hippocampal volume change in mood disorder patients. We first examine published associations between EPO administration, mood disorders, cognition, and hippocampal volume. We then highlight evidence suggesting that GSK3β influences hippocampal volume in MDD patients, and how this could assist with targeting more precise treatments particularly for cognitive deficits in patients with mood disorders. We conclude by suggesting how this developing area of research can be further advanced, such as using pharmacogenetic studies of EPO treatment in patients with mood disorders.
Authors: Becky Inkster, DPhil 1,2,3§, Gwyneth Zai, MD FRCPC, PhD 2,4,5,6, Gemma Lewis, PhD 7, Kamilla W. Miskowiak, PhD 8
1 Wolfson College, University of Cambridge, Cambridge, UK
2 Department of Psychiatry, University of Cambridge, Cambridge, UK
3 Cambridgeshire & Peterborough NHS Foundation Trust, Cambridge, UK
4 Behavioural and Clinical Neuroscience Institute, University of Cambridge, Cambridge, UK
5 Neurogenetics Section, Molecular Brain Science Department, Campbell Family Mental Health Research Institute, and Mood & Anxiety Division, Centre for Addiction and Mental Health, Toronto, Canada
6 Department of Psychiatry, University of Toronto, Toronto, Canada
7 Psychiatric Epidemiology at the Division of Psychiatry, University College London, UK
8 Psychiatric Centre Copenhagen, Copenhagen University Hospital, Rigshospitalet